# Vertex Pharmaceuticals Inc (VRTX) — Stock CV

Vertex Pharmaceuticals Inc is a $129B healthcare company. Revenue grew 10.2% over the last year, and it keeps 35¢ of every dollar of sales as profit. It trades at 29.3× earnings — in the most expensive third of its own history.

> Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally.

## Identity

- **Ticker**: VRTX
- **Sector**: Healthcare
- **Industry**: Biotechnology
- **Headquarters**: BOSTON, MA
- **Employees**: 6 400
- **Website**: https://www.vrtx.com
- **Market cap**: $129B
- **Last price**: $510.00
- **Financial profile**: Mixed

## Vitals (TTM)

- **Revenue**: $12.6B
- **Net income**: $4.41B
- **Free cash flow**: $3.80B
- **P/E**: 29.3
- **Revenue growth (YoY)**: 10.2%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 27 |
| Growth | 72 |
| Profitability | 95 |
| Health | 50 |
| Quality | 55 |
| Moat | 63 |

## Qualifications (beginner checklist) — 9 of 10 passed

- [x] Revenue growing — +10.2% YoY
- [x] Profitable — $4.41B TTM
- [x] Profit growing — +6.1% YoY
- [x] Generates cash — $3.80B TTM
- [x] Debt under control — current ratio 3.19
- [x] Established company — $129B market cap
- [x] Not printing shares — -2.0% shares over ~5y
- [x] Proven track record — 8/10 profitable years
- [ ] Financially stable — health score 50/100
- [x] Valuation not extreme — P/E 29.3

## Experience (career milestones)

- **2026** — Vertex agreed to acquire Crinetics Pharmaceuticals for $10 billion, one of the largest pharma deals of…
- **FY2025** — Best year on record: $3.95B net income
- **FY2024** — Revenue crossed $10B: $11.0B for the year
- **2024** — It was announced Vertex had agreed to acquire the Seattle-headquartered clinical stage…
- **2020** — Semma Therapeutics created a "small, implantable device that holds millions of replacement beta cells, letting…
- **FY2017** — Turned profitable: $263M net income after a loss year
- **FY2016** — Revenue already above $1B: $1.70B in first reported year
- **1989** — Vertex was founded in 1989 by Joshua Boger and Kevin J

## Strengths

- High gross margin (86.0%)
- Strongly profitable — 35.0% net margin
- Revenue growing 10.2% year over year
- Strong cash conversion — FCF is 30.2% of revenue
- Interest covered 72.4× by operating earnings

## Watch-outs

- Loss-making in 2 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $7.57B | $2.34B | $2.41B |
| FY2022 | $8.93B | $3.32B | $3.93B |
| FY2023 | $9.87B | $3.62B | $3.34B |
| FY2024 | $11.0B | -$536M | -$790M |
| FY2025 | $12.0B | $3.95B | $3.19B |

---

Source: https://stockcv.com/VRTX — derived from company filings; may be delayed or incomplete. Information, not investment advice.